GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeStar Therapeutics Corp (OTCPK:GSTC) » Definitions » Valuation Rank

GlobeStar Therapeutics (GlobeStar Therapeutics) Valuation Rank


View and export this data going back to 2011. Start your Free Trial

What is GlobeStar Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

GlobeStar Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of GlobeStar Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

GlobeStar Therapeutics (GlobeStar Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeStar Therapeutics Corp (OTCPK:GSTC) » Definitions » Valuation Rank
Comparable Companies
SONN PKBO SCPS AMPE DRMA PBLA SPRC ADIL INM BXRX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
719 Jadewin Avenue, Richland, WA, USA, 99352
Website
https://www.globestarthera.com
GlobeStar Therapeutics Corp is a clinical-stage Pharmaceutical Company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.
Executives
James C Katzaroff director, officer: CEO 719 JADWIN AVE., RICHLAND WA 99352
William J Farley director 468 ALBERN AVE, OCEANSIDE NY 11572
Robert Chicoski officer: CFO 145 NEWTON ROAD, HAVERHILL MA 01830
Alex K Blankenship director, officer: CEO, Pres., Secr., Treas. 14001 WALDEN RD., SUITE 600, MONTGOMERY TX 77356
Brent Atwood 10 percent owner 5000 RIVERSIDE DR STE100E, IRVING TX 75039
Bruce C Badeau director 770 S. POST OAK LN., STE. 360, HOUSTON TX 77056
Robert W Fryer director 1520 ENCLAVE, # 1208, HOUSTON TX 77077
Robert Federowicz director, officer: Interim CEO & Chairman 495 GRAND BLVD., SUITE 206, MIRAMAR BEACH FL 32550